BRmet50 was derived from our previously implemented meta-analysis of breast cancer gene-expression profiles [7], and PMID18271932Sig33 is derived from TP53 mutation status, which is the most common and fundamental genomic alteration in cancer [39,72]. Here, TP53 is linked to cancer.